Chronic kidney disease (CKD) is a complex disease which affects approximately 13% of the
world's population. Over time, CKD can cause renal dysfunction and progression to end …

Traditional approaches to prevention of the complications of type 2 diabetes (T2D) and
obesity have focused on reduction of blood glucose and body weight. The development of …

Background Large trials have shown that sodium glucose co-transporter-2 (SGLT2)
inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

Background COVID-19 can lead to multiorgan failure. Dapagliflozin, a SGLT2 inhibitor, has
significant protective benefits for the heart and kidney. We aimed to see whether this agent …

Background We conducted a systematic review and meta-analysis of the cardiovascular,
kidney, and safety outcomes of sodium-glucose cotransporter 2 inhibitors (SGLT2i) among …

Background The net absolute effects of sodium-glucose co-transporter-2 (SGLT-2) inhibitors
across different patient groups have not been quantified. Methods We performed a meta …

Kidney lifespan is a patient-oriented outcome that provides much needed context for
understanding chronic kidney disease (CKD). Nephron endowment, age-associated decline …

Kidney disease is a known risk factor for poor outcomes of COVID-19 and many other
serious infections. Conversely, infection is the second most common cause of death in …

Background and aims Scar tissue accumulation in organs is the underlying cause of many
fibrotic diseases. Due to the extensive array of organs affected, the long-term nature of …